Bausch & Lomb raised its sales by 4 percent to $1.16 billion in the third quarter ended Sept. 30, as a decline in sales of ophthalmology products was offset by extra revenues of $67 million from acquisitions. The parent company, Valeant Pharmaceuticals, reported an 11 percent drop in total sales ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.